{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122772","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.054734+00:00","generated_at":"2026-05-30T03:21:19.409132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing","bullets":["Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.","Interim Phase 2 VERONA data: DURAVYU 2.7mg showed +8.9 BCVA letters and -68 μm CST improvement at 16 weeks vs. aflibercept.","First patient dosed in Phase 3 LUGANO trial for wet AMD; second Phase 3 LUCIA first patient dosing expected by end of 2024.","Completed $161M oversubscribed public equity offering at $11.00/share; cash runway extended into 2027.","Opened 40,000 sq ft cGMP commercial manufacturing facility in Northbridge, MA for DURAVYU."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122772","json":"https://secwatch.observer/filing/0000950170-24-122772.json","markdown":"https://secwatch.observer/filing/0000950170-24-122772.md","text":"https://secwatch.observer/filing/0000950170-24-122772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/0000950170-24-122772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/eypt-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:21:19.409132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}